Apitegromab Biosimilar – Anti-pro-GDF-8 mAb – Research Grade from ProteoGenix; catalogue PX-TA1810; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Apitegromab Biosimilar, also known as Anti-pro-GDF-8 monoclonal antibody (mAb), is a research grade therapeutic antibody that is designed to target and inhibit the activity of growth differentiation factor 8 (GDF-8). GDF-8 is a protein that belongs to the transforming growth factor beta (TGF-β) superfamily and is involved in regulating muscle growth and development.
Apitegromab Biosimilar is a fully humanized monoclonal antibody that is produced using recombinant DNA technology. It is composed of two identical heavy chains and two identical light chains, each containing variable and constant regions. The variable regions of the antibody are responsible for binding to the specific target, GDF-8, while the constant regions provide stability and effector functions.
The structure of Apitegromab Biosimilar is similar to that of the endogenous human antibodies, which reduces the risk of immunogenicity and increases its efficacy. The antibody has a molecular weight of approximately 150 kDa and a half-life of 21 days, making it suitable for therapeutic use.
Apitegromab Biosimilar works by binding to GDF-8 and preventing its interaction with its receptor, activin type II receptor (ActRII). This binding inhibits the downstream signaling pathways, such as Smad2/3, which are responsible for regulating muscle growth and differentiation. By blocking the activity of GDF-8, Apitegromab Biosimilar promotes muscle growth and regeneration.
Moreover, Apitegromab Biosimilar also has an Fc region that can interact with immune cells, such as natural killer (NK) cells and macrophages, leading to the destruction of GDF-8-expressing cells. This effector function of the antibody further enhances its therapeutic potential.
Apitegromab Biosimilar has potential applications in the treatment of various muscle-wasting disorders, including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and sarcopenia. These conditions are characterized by a loss of muscle mass and strength, and GDF-8 has been identified as a key factor in their pathogenesis.
Preclinical studies have shown promising results for Apitegromab Biosimilar in animal models of DMD and BMD. It has been found to increase muscle mass and strength, improve muscle function, and reduce fibrosis. The antibody has also been shown to have a synergistic effect when used in combination with other therapies, such as corticosteroids, in DMD treatment.
Furthermore, Apitegromab Biosimilar has potential applications in sports medicine, where it can be used to enhance muscle growth and improve performance. It can also be used in the treatment of age-related muscle loss, or sarcopenia, which is a common problem in the elderly population.
In summary, Apitegromab Biosimilar is a research grade therapeutic antibody that targets GDF-8 and promotes muscle growth and regeneration. Its humanized structure, specific mechanism of action, and potential applications make it a promising candidate for the treatment of muscle-wasting disorders. Further research and clinical trials are needed to fully explore the therapeutic potential of this antibody.
ProteoGenix catalogue number PX-TA1810. For research use only.
Target: Apitegromab Biosimilar – Anti-pro-GDF-8 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Apitegromab Biosimilar – Anti-pro-GDF-8 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
